Crws, Pwrm, Lscc, Tsys - Crwepicks.com Stock Report! Dec 12th 2010

Dec. 12, 2010 - PRLog -- Soon after skin cancer, cancer of the breast is easily the most widespread cancers recognized in females in the united states. But breast cancer rates now have fallen in recent times, even so medical professionals are not certain the key reason why. Even now, for numerous women of all ages, breast cancer could be the condition they will fear most.

Power3 Medical Products Inc (OTC.BB:PWRM) is focused on the development of commercial applications for their proprietary technologies. PWRM engages in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease.

The scientific team is on the leading edge of the proteomics industry through their discovery of protein footprints, pathways, and mechanisms of disease. These discoveries are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer, neurodegenerative disease and drug resistance in cancer. The Company is in a strong competitive position with over 190 identified biomarkers and a state-of-the-art proteomics laboratory.

PWRM delivered four poster presentations at the 2010 International Conference on Alzheimer’s Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, Power3’s diagnostic test, and focused on PWRM ’s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.

President and Chief Scientific Officer of Power3,Dr. Ira L. Goldknopf, commented: “In preparation for commercialization, our objective at this meeting was to show how Power3’s protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer’s disease. It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which PWRM’s protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs.”

PWRM strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies, world class quality procedures and superior research methodologies. The Company will be guided in all of its dealings with its customers, partners, shareholders, associates and investors by the philosophy of best practices.

More about PWRM at: www.Power3Medical.com

******************

Crown Crafts Inc.  announced that E. Randall Chestnut, Chairman, President and Chief Executive Officer, and Olivia Elliott, Vice President and Chief Financial Officer, will present at three upcoming industry conferences:ROTH Infant, Juvenile and Toy Conference, being held December 14, 2010 at the Ganesvoort Park Ave NYC Hotel, North of Madison Square Park.Sidoti & Company Semiannual Micro-Cap Conference, being held January 10, 2011 at the Grand Hyatt New York Hotel in midtown Manhattan.Cowen & Company 9th Annual Consumer Conference, being held January 11, 2011 at the Westin New York at Times Square. Each presentation will be webcast and available for live viewing on the Company's website.

Crown Crafts, Inc., through its subsidiaries, engages in the design, marketing, and distribution of infant and toddler products in the United States and internationally. Its infant products include crib bedding, blankets, nursery accessories, room decor, bibs, burp cloths, bathing accessories, and other infant soft goods. The company?s customers comprise mass merchants, chain stores, juvenile specialty stores, Internet accounts, wholesale clubs, and catalogue and direct mail houses.

******************

Lattice Semiconductor Corporation  reiterated on December 09, 2010, its guidance for the fourth quarter ending January 1, 2011.Fourth quarter revenue is expected to be down 2% to 7% on a sequential basis.Gross margin percentage is expected to be approximately 58% to 60% of revenue.Total operating expenses are expected to be approximately $34.0 million. The majority of the sequential increase is related to new product launch expenses and associated mask costs.Lattice also reiterates its expectation for continued profitability.

Lattice Semiconductor Corporation designs, develops, and markets programmable logic products and related software. It offers field programmable gate array (FPGA) products, including LatticeECP family for deployment in wireless infrastructure and wireline access equipment, as well as in video and imaging applications; LatticeXP for the security, surveillance, and display markets.

******************

TeleCommunication Systems Inc.  announced on December 10, 2010 that it has been named the awardee of a competitive five-year contract (a base plus five option periods) valued at approximately $49 million to provide the Department of Defense's (DoD's) military and civilian personnel with on-site computer network operations (CNO) training to support the government's cyber security workforce development. The government's workforce development effort is a key Obama administration initiative and is one of White House Cyber Security Coordinator Howard Schmidt's top priorities.

TeleCommunication Systems, Inc. develops and applies secure mobile communication technology in the United States and internationally. The company operates in two segments, Commercial and Government. The Commercial segment offers commercial services and systems that enable wireless carriers to deliver short text messages, location-based information, Internet content, and other enhanced communication services to and from wireless phones.


*******************************************
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
*******************************************





******************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more at http://crwepicks.com/disclaimer ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings, Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings, Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings, Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings, Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).